|
|
|
 |
Search published articles |
 |
|
Showing 2 results for Prostate Cancer
Ameri A, Alidousti A, Mojir Sheibani Kh, Ghanbari Motlagh A, Valaei N, Emranpour Mh, Abbaszadegan Mr, Hosseini Y, Parvin M,
Volume 13, Issue 6 (2-2009)
Abstract
Background: With regard to the increasing prevalence and mortality rate of prostate cancer and several related reports studying the role of promoter Hypermethylation of RARB and p16 in predicting the prognosis, this research is carried out on 3 groups of subjects with poor prognostic factors (case), good prognostic factors (control-2) and healthy person (control-1), at three general hospitals of Imam Hossein, Modarres and Labbafineyhad, between 2007-2009. Materials and Methods: The research has case-control Design. All three goup of participants (21 subjects in each group) were analyzed for hypermethylation of RARB- p16. All groups were matched for age, tumor stage, grade & PSA. The technique was methylation specific polymerase chain reaction (MSPCR). Results: In control-1, no methylation of RARB were observed. In control-2, RARB was positive in 33%. In case group, the RARB was positive for 71.4%. For control 2 and case groups, the RAR positivity was higher than control-1 (P< 0.001), however, that of case group was higher than control-2(p
Mansoor Jamali Zawarei, Mohammad Reza Nowroozi, Mohsen Ayati, Hasan Jamshidian, Bentolhoda Rajaei, Faeze Ghasemi,
Volume 19, Issue 2 (6-2014)
Abstract
Background and Aim: We conducted this study to evaluate and compare the sensitivity and specificity of various para-clinic parameters in detecting prostate cancer. Materials and Methods: In this cross-sectional study, 220 patients who underwent prostate biopsies for either high serum PSA level or abnormal digital rectal examination. Sensitivity and specificity of serum PSA, free to total PSA ratio and transrectal ultrasonography findings were calculated. Results: Based on the pathological findings in 220 cases, 25% were diagnosed with prostate cancer. The mean age of patients with prostate cancer was 69.118.6 years. Mean serum PSA level among prostate cancer patients was significantly higher than in other patients (19.517.5 ng/dl vs. 10.58.1 ng/dl) (P=0.003). The sensitivity and specificity of PSA for detecting prostate cancer, considering cut-off value of 4 ng/dl, was 92% and 2%, respectively. Free to total PSA ratio with cut-off value of 10% revealed 82% sensitivity and 17% specificity. Moreover, hypoechoic lesions detected by transrectal ultrasound had a sensitivity and specificity of 34% and 93%, respectively. Conclusion: combination of different PSA related parameters with tranrectal ultrasound findings might increase sensitivity and specificity in detecting prostate cancer and reduce unnecessary biopsies.
|
|
